ArticleBiochemistry and biophysics reports2026
Quantitative dot blot method for measuring EGFR protein levels in patients with colorectal cancer.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The expression levels of the epidermal growth factor receptor (EGFR) may be associated with the efficacy of cetuximab (CTX); however, conventional immunohistochemical assays lack quantitative accuracy and standardization, thereby making it hard to achieve absolute quantification of protein expression and cross-platform comparisons. To establish an objective quantitative standard for EGFR protein expression levels, we employed quantitative dot blotting (QDB) to analyze tumor samples from patients with RAS/BRAF wild-type colorectal cancer (CRC). Materials and methods: We collected 89 formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens from patients with CRC stored at Yuhuangding Hospital in Yantai for QDB testing. Of these, 42 served as untreated controls, and 47 patients received CTX treatment. Results: EGFR protein levels in all patients with CRC ranged from 0.05 to 3.85 nmol/g (n = 89). Using the predefined cohort-wide cutoff of 0.23 nmol/g, a chi-square test performed using the Statistical Package for the Social Sciences software revealed that patients with low EGFR expression had longer overall survival, regardless of CTX treatment. Conclusions: This study established a QDB-based assay capable of quantitatively and objectively measuring EGFR protein levels in CRC specimens. This assay helps establish the value of EGFR protein as a predictive biomarker and is expected to assist in the retrospective and prospective evaluation of anti-EGFR therapies in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.